Bizily Scott, Chief Legal Officer of 4D Molecular Therapeutics ($FDMT), made six open market sales of company shares over the past year, totaling $127 thousand. Her most recent sale occurred on December 16, 2025. These transactions rank 9,221st out of 11,678 insiders by sale value, well below the average of $8.6 million and 6.4 sales per insider. Bizily Scott reported no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 25, 2026 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | A | Stock Option (Right to Buy) | 217000 | $0.00 | 217,000.0000 | 57,135,075 | 9999.99% | 0.38% |
| Dec. 16, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right to Buy) | 1635 | $0.00 | 73,595.0000 | 57,135,075 | 2.17% | 0.00% |
| Dec. 16, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1635 | $10.90 | 3,594.0000 | 57,135,075 | 31.27% | 0.00% |
| Dec. 16, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1635 | $4.14 | 5,229.0000 | 57,135,075 | 45.49% | 0.00% |
| Nov. 17, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1635 | $4.14 | 5,229.0000 | 57,135,075 | 45.49% | 0.00% |
| Nov. 17, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1635 | $10.59 | 3,594.0000 | 57,135,075 | 31.27% | 0.00% |
| Nov. 17, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right to Buy) | 1635 | $0.00 | 75,230.0000 | 57,135,075 | 2.13% | 0.00% |
| Oct. 24, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 2678 | $12.00 | 3,594.0000 | 46,302,407 | 42.70% | 0.01% |
| Oct. 24, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right to Buy) | 1084 | $0.00 | 9,295.0000 | 46,302,407 | 10.44% | 0.00% |
| Oct. 24, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1084 | $6.49 | 6,272.0000 | 46,302,407 | 20.89% | 0.00% |
| Oct. 16, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right to Buy) | 1635 | $0.00 | 76,865.0000 | 46,302,407 | 2.08% | 0.00% |
| Oct. 16, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1635 | $10.17 | 5,188.0000 | 46,302,407 | 23.96% | 0.00% |
| Oct. 16, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1635 | $4.14 | 6,823.0000 | 46,302,407 | 31.52% | 0.00% |
| Oct. 9, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 2408 | $10.00 | 5,188.0000 | 46,302,407 | 31.70% | 0.01% |
| Sept. 23, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 2407 | $8.00 | 7,596.0000 | 46,302,407 | 24.06% | 0.01% |
| March 6, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | A | Stock Option (Right to Buy) | 78500 | $0.00 | 78,500.0000 | 46,302,407 | 9999.99% | 0.17% |
| Sept. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 7,281.0000 | 0 | 7.37% | 0.00% |
| Sept. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 10,379.0000 | 0 | 4.60% | 0.00% |
| Sept. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 500 | $16.33 | 6,781.0000 | 0 | 6.87% | 0.00% |
| Aug. 19, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 500 | $15.00 | 6,781.0000 | 0 | 6.87% | 0.00% |
| Aug. 19, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 10,879.0000 | 0 | 4.39% | 0.00% |
| Aug. 19, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 7,281.0000 | 0 | 7.37% | 0.00% |
| July 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 11,379.0000 | 0 | 4.21% | 0.00% |
| July 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 7,281.0000 | 0 | 7.37% | 0.00% |
| July 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1250 | $8.04 | 8,531.0000 | 0 | 17.17% | 0.00% |
| July 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1750 | $27.11 | 6,781.0000 | 0 | 20.51% | 0.00% |
| July 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1250 | $0.00 | 32,502.0000 | 0 | 3.70% | 0.00% |
| July 11, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1996 | $0.00 | 23,004.0000 | 0 | 7.98% | 0.00% |
| July 11, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1996 | $15.78 | 8,777.0000 | 0 | 29.44% | 0.00% |
| July 11, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1996 | $25.00 | 6,781.0000 | 0 | 22.74% | 0.00% |
| July 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 2916 | $0.00 | 33,752.0000 | 0 | 7.95% | 0.00% |
| July 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1332 | $0.00 | 11,879.0000 | 0 | 10.08% | 0.00% |
| July 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 4248 | $21.36 | 1,737.0000 | 0 | 70.98% | 0.00% |
| July 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 2916 | $8.04 | 5,985.0000 | 0 | 95.01% | 0.00% |
| July 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1332 | $6.49 | 3,069.0000 | 0 | 76.68% | 0.00% |
| June 17, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1250 | $8.04 | 3,487.0000 | 0 | 55.88% | 0.00% |
| June 17, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 13,211.0000 | 0 | 3.65% | 0.00% |
| June 17, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1250 | $0.00 | 36,668.0000 | 0 | 3.30% | 0.00% |
| June 17, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 2,237.0000 | 0 | 28.79% | 0.00% |
| June 17, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1750 | $23.71 | 1,737.0000 | 0 | 50.19% | 0.00% |
| May 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1250 | $0.00 | 37,918.0000 | 0 | 3.19% | 0.00% |
| May 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 13,711.0000 | 0 | 3.52% | 0.00% |
| May 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1250 | $8.04 | 3,487.0000 | 0 | 55.88% | 0.00% |
| May 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 2,237.0000 | 0 | 28.79% | 0.00% |
| May 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 467 | $25.75 | 1,737.0000 | 0 | 21.19% | 0.00% |
| May 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1283 | $25.34 | 2,204.0000 | 0 | 36.79% | 0.00% |
| April 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 14,211.0000 | 0 | 3.40% | 0.00% |
| April 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 2,237.0000 | 0 | 28.79% | 0.00% |
| April 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1250 | $8.04 | 3,487.0000 | 0 | 55.88% | 0.00% |
| April 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1750 | $25.74 | 1,737.0000 | 0 | 50.19% | 0.00% |
| April 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1250 | $0.00 | 39,168.0000 | 0 | 3.09% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1332 | $0.00 | 14,711.0000 | 0 | 8.30% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 2916 | $0.00 | 40,418.0000 | 0 | 6.73% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1996 | $0.00 | 21,008.0000 | 0 | 8.68% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1909 | $0.00 | 46,182.0000 | 0 | 3.97% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1332 | $6.49 | 3,069.0000 | 0 | 76.68% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 2916 | $8.04 | 5,985.0000 | 0 | 95.01% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1996 | $15.78 | 7,981.0000 | 0 | 33.35% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1909 | $20.24 | 9,890.0000 | 0 | 23.92% | 0.00% |
| April 1, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 8153 | $31.78 | 1,737.0000 | 0 | 82.44% | 0.00% |
| March 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 4342 | $25.98 | 6,079.0000 | 0 | 249.97% | 0.00% |
| March 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 5833 | $35.04 | 1,737.0000 | 0 | 77.05% | 0.00% |
| March 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 4342 | $0.00 | 55,658.0000 | 0 | 7.24% | 0.00% |
| March 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1491 | $0.00 | 54,167.0000 | 0 | 2.68% | 0.00% |
| March 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1491 | $25.98 | 7,570.0000 | 0 | 24.53% | 0.00% |
| March 18, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1250 | $8.04 | 3,487.0000 | 0 | 55.88% | 0.00% |
| March 18, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1750 | $31.27 | 1,737.0000 | 0 | 50.19% | 0.00% |
| March 18, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 16,043.0000 | 0 | 3.02% | 0.00% |
| March 18, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1250 | $0.00 | 43,334.0000 | 0 | 2.80% | 0.00% |
| March 18, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 2,237.0000 | 0 | 28.79% | 0.00% |
| Feb. 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1909 | $0.00 | 48,091.0000 | 0 | 3.82% | 0.00% |
| Feb. 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1909 | $30.00 | 1,737.0000 | 0 | 52.36% | 0.00% |
| Feb. 27, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1909 | $20.24 | 3,646.0000 | 0 | 109.90% | 0.00% |
| Feb. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1250 | $8.04 | 3,487.0000 | 0 | 55.88% | 0.00% |
| Feb. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 1250 | $0.00 | 44,584.0000 | 0 | 2.73% | 0.00% |
| Feb. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 500 | $6.49 | 2,237.0000 | 0 | 28.79% | 0.00% |
| Feb. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right To Buy) | 500 | $0.00 | 16,543.0000 | 0 | 2.93% | 0.00% |
| Feb. 16, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1750 | $27.67 | 1,737.0000 | 0 | 50.19% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right to Buy) | 2916 | $0.00 | 45,834.0000 | 0 | 5.98% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right to Buy) | 1332 | $0.00 | 17,043.0000 | 0 | 7.25% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Stock Option (Right to Buy) | 1996 | $0.00 | 23,004.0000 | 0 | 7.98% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1996 | $27.50 | 1,737.0000 | 0 | 53.47% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1996 | $15.78 | 3,733.0000 | 0 | 114.91% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 2916 | $27.50 | 1,737.0000 | 0 | 62.67% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 2916 | $8.04 | 4,653.0000 | 0 | 167.88% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | S | Common Stock | 1332 | $27.50 | 1,737.0000 | 0 | 43.40% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Bizily Scott | Chief Legal Officer | M | Common Stock | 1332 | $6.49 | 3,069.0000 | 0 | 76.68% | 0.00% |